NCCN Guidelines Updated
Flash Update Sent September 16, 2011
NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Hodgkin Lymphoma. These NCCN Guidelines are currently available as Version 3.2011.
- Brentuximab vedotin was added as a treatment option for patients with relapsed or progressive disease with the following footnote: "Brentuximab vedotin is a treatment option for patients who have failed HDT/ASCR or at least 2 prior multi-agent chemotherapy regimens."
Flash Update Sent September 12, 2011
NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Breast Cancer Risk Reduction. These NCCN Guidelines are currently available as Version 3.2011.
- For postmenopausal women desiring risk reduction therapy, exemestane has been added to the list of risk reduction agents as a category 1 option with a footnote stating, "Other aromatase inhibitors have shown prevention of contralateral breast cancer and there are ongoing clinical trials."
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.